Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. Among authors: schneider c. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk.
Winkler D, Schneider C, Zucknick M, Bögelein D, Schulze K, Zenz T, Mohr J, Philippen A, Huber H, Bühler A, Habermann A, Benner A, Döhner H, Stilgenbauer S, Mertens D. Winkler D, et al. Among authors: schneider c. Haematologica. 2010 Nov;95(11):1880-8. doi: 10.3324/haematol.2010.025734. Epub 2010 Aug 16. Haematologica. 2010. PMID: 20713460 Free PMC article.
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Steinbrecher D, et al. Among authors: schneider c. Leuk Lymphoma. 2018 Jul;59(7):1614-1623. doi: 10.1080/10428194.2017.1390236. Epub 2017 Oct 24. Leuk Lymphoma. 2018. PMID: 29063805 Clinical Trial.
Targeted therapy in CLL: changing the treatment paradigm.
Schneider C, Steinbrecher D, Stilgenbauer S. Schneider C, et al. Oncotarget. 2019 Jun 18;10(40):4002-4003. doi: 10.18632/oncotarget.26964. eCollection 2019 Jun 18. Oncotarget. 2019. PMID: 31258844 Free PMC article. No abstract available.
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, V Tresckow J, Lange E, Kiehl M, Dreyling M, Ritgen M, Dürig J, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Fischer K, Goede 5th, Hallek M, Eichhorst B. Al-Sawaf O, et al. Among authors: schneider c. Leukemia. 2021 Jan;35(1):169-176. doi: 10.1038/s41375-020-0797-x. Epub 2020 Mar 17. Leukemia. 2021. PMID: 32203141 Clinical Trial.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Lurà MP, Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. Tausch E, et al. Among authors: schneider c. Blood. 2020 Jun 25;135(26):2402-2412. doi: 10.1182/blood.2019004492. Blood. 2020. PMID: 32206772 Free article.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, Davis Z, Yan XJ, Jeromin S, Schneider C, Pedersen LB, Tschumper RC, Sutton LA, Baliakas P, Scarfò L, van Gastel EJ, Armand M, Tausch E, Biderman B, Baer C, Bagnara D, Navarro A, Langlois de Septenville A, Guido V, Mitterbauer-Hohendanner G, Dimovski A, Brieghel C, Lawless S, Meggendorfer M, Brazdilova K, Ritgen M, Facco M, Tresoldi C, Visentin A, Patriarca A, Catherwood M, Bonello L, Sudarikov A, Vanura K, Roumelioti M, Skuhrova Francova H, Moysiadis T, Veronese S, Giannopoulos K, Mansouri L, Karan-Djurasevic T, Sandaltzopoulos R, Bödör C, Fais F, Kater AP, Panovska I, Rossi D, Alshemmari S, Panagiotidis P, Costeas P, Espinet B, Antic D, Foroni L, Montillo M, Trentin L, Stavroyianni N, Gaidano G, Francia di Celle P, Niemann C, Campo E, Anagnostopoulos A, Pott C, Fischer K, Hallek M, Oscier D, Stilgenbauer S, Haferlach C, Jelinek D, Chiorazzi N, Pospisilova S, Lefranc MP, Kossida S, Langerak AW, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Agathangelidis A, et al. Among authors: schneider c. Blood. 2021 Mar 11;137(10):1365-1376. doi: 10.1182/blood.2020007039. Blood. 2021. PMID: 32992344 Free PMC article.
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).
Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S. Jaramillo S, et al. Among authors: schneider c. Haematologica. 2020 Nov 1;105(11):2598-2607. doi: 10.3324/haematol.2019.231027. Haematologica. 2020. PMID: 33131249 Free PMC article.
3,571 results